Molecular Hybrids of Quinoline and Sulfonamide: Design, Synthesis and in Vitro Anticancer Studies.

Molecular hybrids of diversely functionalized quinoline and sulfonamide have been designed. Multistep synthetic strategies have been used for the synthesis. The anti‐cancer properties have been evaluated against various cancer cell lines including HCT116, A549, U2OS, CCRF‐CEM, Jurkat, MOLT‐4, RAMOS, and K562. Non‐cancer cell lines MRC‐5 and BJ were also included for comparison. When examining the effects on A549, HCT116, and U2OS cells, all tested compounds exhibited limited potency with IC50 values exceeding 50 μM, indicating weak activity against these cell lines. Against the ITK high cells <italic>Viz</italic>. are Jurkat, CCRF‐CEM and MOLT‐4, <bold>9 e, 9 p</bold> and <bold>9 j</bold> found to the maximum potent compounds with IC50 values of 7.43±7.40 μM, 13.19±1.25 μM and 5.57±7.56 μM respectively. Similarly, in the BTK high cells screenings, <bold>9 n</bold> and <bold>9 e</bold> molecules with an IC50 value of 2.76±0.79 μM and 5.47±1.71 μM against RAMOS and K562 respectively are highly potent. Interestingly, all the molecules have exhibited IC50 value >50 μM against the non‐cancer cells (MRC‐5 and BJ), which indicates the promising non‐cytotoxic nature of the molecules. [ABSTRACT FROM AUTHOR]